Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering
- None.
- None.
The public offering from Motus GI Holdings represents a strategic move to raise capital, which is critical for the company's growth and development. The offering structure, including common stock and Series A and B warrants, is designed to attract a range of investors. The immediate exercisability of the warrants provides flexibility and an incentive for investors to potentially increase their investment in the company at a later date.
However, the pricing at $1.50 per share, with an exercise price equal to the offering price for both Series A and Series B warrants, suggests a potential undervaluation or a need for quick capital infusion, which could be indicative of underlying financial challenges. Investors should consider the dilutive effect of such an offering on existing shares and the implications for shareholder value.
Long-term effects depend on how the raised capital is utilized. If invested wisely in product development or market expansion, it could lead to growth and increased market share, which would benefit investors. Conversely, if the capital does not yield the expected returns, it could lead to further dilution or financial strain.
For businesses operating in the medical technology sector, offerings like this are often used to fund research and development or to expand commercialization efforts for their products. Given that Motus GI is focused on improving endoscopic outcomes and experiences, the proceeds from this offering could significantly impact its ability to innovate and compete in the market.
The success of such offerings can also be an indicator of market confidence in a company's future prospects. The terms of the warrants indicate that investors are being given an opportunity to commit further to the company's success, but the relatively short expiration of the Series B warrants might suggest an expectation of short-term gains or developments.
It is important for stakeholders to analyze the company's track record, management's ability to execute on business plans and the competitive landscape. The impact of this offering on the company's financial health and stock performance will be closely watched by the market.
Investors evaluating this offering must consider both the opportunity and the risks involved. The structure of the offering, with pre-funded warrants exercisable at nearly zero cost, is designed to minimize upfront cash outlay for investors, which could be attractive for those who believe in the company's long-term potential but are cautious about its short-term prospects.
It's essential for investors to scrutinize the company's use of proceeds statement and its recent financial performance. The capital raised should ideally be allocated towards activities that drive revenue growth and operational efficiency. Investors should also be aware of the potential for stock price volatility following the offering, as the market absorbs the new shares and warrants.
Given the nature of the healthcare industry, where product development cycles can be lengthy and capital-intensive, this offering could be a pivotal moment for Motus GI. The company's ability to capitalize on this influx of capital will be a determining factor in its future success and the long-term performance of its stock.
FORT LAUDERDALE, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus GI” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today the pricing of a public offering of 3,333,334 shares of common stock (or pre-funded warrants in lieu thereof), Series A common warrants to purchase up to 3,333,334 shares of common stock, and Series B common warrants to purchase up to 3,333,334 shares of common stock, at a combined public offering price of
The closing of the offering is expected to occur on or about December 21, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds of this offering for working capital and other general corporate purposes.
A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333- 275121) previously filed with the Securities and Exchange Commission (SEC) which became effective on December 18, 2023. The offering is being made only by means of a prospectus forming part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. An electronic copy of the final prospectus will be filed with the SEC and may be obtained, when available, on the SEC’s website located at http://www.sec.gov and may also be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Motus GI Holdings, Inc.
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
For more information, visit www.motusgi.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms, including without limitation, statements relating to the satisfaction of customary closing conditions related to the offering and uncertainties related to the offering and the use of proceeds from the offering, risks related to market and other conditions, risks inherent in the development and commercialization of potential products, possible or assumed future results of operations, business strategies, potential grow opportunities, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s quarterly and annual reports filed with the Securities and Exchange Commission, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact:
Troy Williams
LifeSci Advisors
(518) 221-0106
twilliams@lifesciadvisors.com
FAQ
What did Motus GI Holdings, Inc. announce?
What is the public offering price of the shares?
How much gross proceeds did the offering result in?
When is the closing of the offering expected to occur?
